Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
Roberta D’Ambrosio(University of Southern California), Pietro Lampertico(University of Milan), Angelo Sangiovanni(Ospedale Maggiore), Vana Sypsa(National and Kapodistrian University of Athens), Maria Paola Anolli(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Marta Borghi(University of Milan), Ilaria Fanetti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Riccardo Perbellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Giulia Tosetti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Elisabetta Degasperi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Iavarone(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), R. Soffredini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 75
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
The natural history of compensated cirrhosis due to hepatitis C virus
|Hepatology|2006|631
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance☆
|Gastroenterology|2004|607
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
|Hepatology|2012|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|392